Immunosuppression for dual kidney transplantation with marginal organs: the old is better yet

Am J Transplant. 2007 Mar;7(3):639-44. doi: 10.1111/j.1600-6143.2007.01671.x. Epub 2007 Jan 11.

Abstract

Immunosuppressive protocols in dual kidney transplantation (DKT) are based on calcineurin inhibitors (CNI). We wonder whether a CNI-free immunosuppression can improve outcome in older patients receiving a DKT with marginal donor organs. Thirty-six were treated with CsA, MMF and prednisone (CsA group) and 42 with rATG, SRL, MMF and prednisone (SRL group). Incidence of delayed graft function and acute rejection was 44% and 11% in the CsA group, and 40% and 8% in the SRL group. CMV infection incidence was low in both protocols. Three-year patient survival was 89% in the CsA and 76% in the SRL group. One- and 3-year graft survival after censoring for dead with a functioning allograft was 94.2% and 94% in CsA and 95% and 90% in SRL, respectively. Renal function was similar in both groups whereas proteinuria was higher in the SRL group. Uninephrectomy due to graft thrombosis or urinary-related complications was numerically higher in the SRL (21%) than in the CsA group (8%) (p = 0.13) and it was associated with renal failure and proteinuria. In DKT, a new induction immunosuppressive protocol based on rATG, SRL, MMF and prednisone does not offer any advantage in comparison to the old CsA, MMF and prednisone.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Calcineurin Inhibitors
  • Cardiovascular Diseases / prevention & control
  • Cyclosporine / therapeutic use
  • Delayed Graft Function / prevention & control
  • Drug Therapy, Combination
  • Female
  • Graft Rejection / prevention & control
  • Graft Survival
  • Humans
  • Immunosuppression Therapy / methods*
  • Kidney Failure, Chronic / surgery*
  • Kidney Transplantation / immunology*
  • Kidney Transplantation / mortality*
  • Male
  • Middle Aged
  • Mycophenolic Acid / therapeutic use
  • Postoperative Complications / prevention & control*
  • Prednisone / therapeutic use
  • Risk
  • Treatment Outcome

Substances

  • Calcineurin Inhibitors
  • Cyclosporine
  • Mycophenolic Acid
  • Prednisone